Abstract 6689: Single-Dose YKYY029, an Angiotensinogen-Targeting Small Interfering RNA, in Healthy and Mildly Hypertensive Subjects: A Phase 1 Study
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.6689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Fangfang Wang und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Angiotensinogen (AGT), produced predominantly by the liver, is the exclusive precursor for angiotensin peptides and the most upstream substrate of the renin-angiotensin-aldosterone system (RAAS). Sustained hepatic AGT silencing may provide long-acting blood pressure (BP) lowering and help overcome the severe adherence limitations of daily oral pharmacotherapy. YKYY029 is a novel GalNAc-conjugated small interfering RNA (siRNA) designed to potently and selectively silence hepatic AGT mRNA expression. Research Question/Hypothesis: We evaluated whether a single subcutaneous dose of YKYY029 would produce early and sustained AGT lowering, accompanied by exploratory ambulatory BP reductions, while maintaining an acceptable safety profile.
Methods
This ongoing randomized, double-blind, placebo-controlled, single-ascending-dose phase 1 study enrolled Chinese healthy volunteers and adults with mild essential hypertension who were untreated or off antihypertensive therapy for >=4 weeks. Participants received a single abdominal subcutaneous injection of YKYY029 (50, 150, 300, 600, or 800 mg) or placebo (6:2 allocation per cohort). Safety, serum AGT, anti-drug antibodies, ambulatory BP, and office BP were assessed through 12 weeks.
Results
Forty participants were dosed (YKYY029, n=30; placebo, n=10; baseline 24-hour ambulatory BP, 127.9/82.3 mm Hg). No deaths, serious adverse events, adverse events of special interest, TEAE-related interruption/discontinuation, related grade >=3 TEAEs, hypotension/syncope, or anti-drug antibodies occurred. Injection-site erythema and pain each occurred in 1/30 YKYY029-treated participants. Serum AGT reductions were rapid, dose-associated, and durable: by Day 30, mean reductions were 88.2%, 94.8%, 92.5%, 97.9%, and 97.4% for the 50, 150, 300, 600, and 800 mg groups, respectively, and remained 81.8%, 93.2%, 94.0%, 97.6%, and 97.9% at Day 85 (study ongoing; Figure 1). At Day 85, 24-hour ambulatory SBP changes across 50/150/300/600/800 mg were -9.7/-12.5/-4.8/-11.0/-17.7 mm Hg (placebo +1.4). For 150/800 mg, 24-hour SBP/DBP changes were -12.5/-12.5 and -17.7/-11.8 mm Hg; descriptive placebo-adjusted changes were -13.9/-8.0 and -19.1/-7.3 mm Hg; SBP percent changes were -9.7% and -13.5% versus +1.2% with placebo. Daytime/nighttime SBP/DBP changes were -13.3/-13.5 and -11.5/-8.5 mm Hg at 150 mg, and -18.8/-12.8 and -13.7/-9.3 mm Hg at 800 mg (Figure 2).
Conclusions
A single dose of YKYY029 was generally well tolerated and produced highly rapid, near-complete, sustained hepatic AGT suppression with both daytime and nighttime ambulatory BP reductions through Week 12. These findings support the continued clinical advancement of YKYY029 as an infrequent, long-acting foundational therapy for hypertension management.
Zitieren
APA
Wang, F., Huang, Z., Zhou, Y., Zhu, J., Liu, Z., Bai, M., Han, S., Yuan, Y., Tang, S., Yang, J., Han, S., & Li, H. (2026). Abstract 6689: Single-Dose YKYY029, an Angiotensinogen-Targeting Small Interfering RNA, in Healthy and Mildly Hypertensive Subjects: A Phase 1 Study. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.6689
Vancouver
Wang F, Huang Z, Zhou Y, Zhu J, Liu Z, Bai M, et al. Abstract 6689: Single-Dose YKYY029, an Angiotensinogen-Targeting Small Interfering RNA, in Healthy and Mildly Hypertensive Subjects: A Phase 1 Study. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.6689
BibTeX
@article{Wang2026,
author = {Wang, Fangfang and Huang, Zeao and Zhou, Yuting and Zhu, Jixiang and Liu, Zhiping and Bai, Man and Han, Shaowei and Yuan, Yuping and Tang, Shunan and Yang, Junbo and Han, Shaowei and Li, Haiyan},
title = {Abstract 6689: Single-Dose YKYY029, an Angiotensinogen-Targeting Small Interfering RNA, in Healthy and Mildly Hypertensive Subjects: A Phase 1 Study},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.6689}
}
EUVIMED